Annex 1

Competition announcement for the assignment of 1 research grant at the University of Udine, entitled “The additive effect of ketamine in combination with electroconvulsive stimulation (ECS) in major depressive disorder (MDD): a translational study” SSD: MED/41 (principal investigator, Tiziana Bove)

Research grant funded by the resources of the project PRIN 2022 - Prot. n. 20227EA9AN

Art. 1

A selection procedure is hereby launched for the award of 1 research grant at the University of Udine, as identified in Attachment A which constitutes an integral part of the present announcement.

The research grant is linked to the research project and is subject and conditioned upon the relative funding.

The fellowship may be renewed, in compliance with Art. 22, Law No. 240 of 30 December 2010 (as in the text in force before the implementation of the Conversion Law of the D.L. 36/2022, L. 79/2022), Law No. 11 of 27 February 2015, and the current regulations of the University of Udine for awarding research grants, issued with the Rector’s Decree No. 182 of 31 March 2021. The renewal is subject to the scientific coordinator’s positive assessment of the researcher’s activities, an adequate scientific rationale, and a corresponding financial covering.

The research fellowship does not give rise to any right with regards to accessing University posts.

Any personal communication to candidates related to this selection will be sent exclusively to the email address indicated when registering for the selection, as mentioned in Art. 5.

Art. 2

The research grant described in this competition announcement and the required qualifications to apply for the position are identified in Attachment A. The lack of the admission requirements leads to the automatic exclusion from the competition procedure.

Possession of a PhD or equivalent degree obtained abroad or, only for the interested areas, of a medical specialization accompanied by an adequate scientific production, constitutes a preferential...
qualification for awarding the research fellowship of this selection, if it has not been provided as a mandatory requirement.

Candidates in possession of a specialization qualification in the medical area obtained abroad must also attach the recognition decrees issued by the Italian Ministry of Health in order to avail themselves of the qualification of specialist doctor and of the title of surgeon. These recognition decrees are also required if the qualification has already been recognized in another country of the European Union. http://www.salute.gov.it/ProfessioniSanitariePubblico/

For the only purpose of the admission to the competition, the Examining Board (Art. 7) shall assess the equivalence of the qualification obtained abroad, except for the evaluation of the medical specialization qualification to which Article 38 of the Legislative Decree 165/2001 and subsequent modifications and additions, and EU regulations on the matter, shall be applied.

The Examining Board will proceed to the evaluation of the qualification obtained abroad according to the documentation attached to the application form. The Examining Board may exclude the candidate if the submitted documentation does not provide sufficient information for the assessment. Therefore, applicants must enclose all the documentation in their possession relating to their qualification in order to provide the Examining Board with sufficient information for assessment.

Candidates holding a qualification issued by a European Research Area country, if successful, must submit, if not already attached to the application form one of the following options:
- Supplement Diploma in English issued by the competent University.
- CIMEA Certificate of comparability of the foreign qualification, issued by CIMEA (Information Centre on Academic Mobility and Equivalence) via the "diplome" service at https://cimea.dipломa.eu/udine/#/auth/login

Candidates holding a qualification issued by a non-European Research Area country, if successful, must submit, if not already attached to the application form one of the following options:
- Declaration of the on-site value of the qualification and the certificate relating to the degree with examinations and grades. A certificate in a language other than Italian or English must be accompanied by an official translation into one of these languages (certified by the competent diplomatic-consular authority or certified by a court in Italy).
- CIMEA Certificate of comparability of the foreign qualification, issued by CIMEA (Information Centre on Academic Mobility and Equivalence) via the "diplome" service at https://cimea.dipлома.eu/udine/#/auth/login

If the Supplement Diploma or the statement/attestation of comparability are not available when signing the contract, the applicant must demonstrate that he/she has requested the documentation and submit it as soon as possible.

Any exclusion from the selection procedure due to lack of eligibility requirements, absence of required documents, failure to sign the selection application or submission of the selection application in a manner different from what is provided for in this call for applications will be communicated to applicants exclusively at the email address indicated in the application form.
Art. 3

The research grant referred to in this call for applications cannot be awarded:

a. to employees of Universities and the entities referred to in Article 22, section 1, of Italian Law no. 240 of 30 December 2010 (in the text prior to the reform introduced by Law no. 79 of 29 June 2022);

b. to those who have already been awarded research grants pursuant to Italian Law no. 240 of 30 December 2010 (prior to the reform introduced by Law no. 79 of 29 June 2022) for the maximum period provided by law, even if not continuously, excluding the period in which the grant was used in conjunction with the doctorate, up to the legal term of the relative course;

c. to those who have already benefited from research grants and fixed-term researcher contracts provided for, respectively, in Articles 22 and 24 of Italian Law no. 240 of 30 December 2010 (in the text prior to the reform introduced by Law no. 79 of 29 June 2022), for a total of 12 years, even if not consecutive;

d. to anyone who has a degree of kinship or affinity, up to and including the fourth degree, with:
   - the Rector, the Director General or a member of the Board of Directors of the University of Udine;
   - the scientific supervisor or a professor/researcher belonging to the department or organisation hosting the research grant in question.

The research grant provided for in this call for applications cannot be combined:

a) with scholarships of any kind, except for those granted by Italian or foreign institutions to supplement, by means of stays abroad, the fellow's training or research activities;

b) with other research grants;

c) with an employment relationship, even if part-time, without prejudice to the relevant provisions for employees of public administrations.

The grant awarded under this call for applications is also incompatible with simultaneous attendance at university degree courses, either Bachelor's degree or Master’s degree courses, research Doctorates with scholarships and medical specializations, in Italy or abroad.

Art. 4

Applicants must enclose with their application, under penalty of exclusion, the following documents:

a) their professional scientific CV, highlighting the candidate's aptitude for carrying out and implementing the research project (Attachment A);

b) their identity card, their passport or any other identification document¹;

c) (for candidates with a foreign qualification only) certification or self-certification of both the academic qualification required for the admission to the selection, and of the exams (with evaluation) took during the period of study abroad, and of any other document that can be useful to the evaluation of the degree by the Examining Board.

Applicants can attach to the application, publications and any other certification considered useful to demonstrate the qualification based on the research program (Attachment A) and to certify any research activity accomplished at public or private institutes (indicating the starting and ending date and the duration).

The documents and qualifications mentioned above must be submitted in Italian or English. Those that are not as requested will not be evaluated. Documents originally written in a language other than

---

¹ Please be aware that the residence permit is not an identification document.
Italian or English must come with a translation in Italian or English, that the candidate will do on its own responsibility. The translation can be an abstract concerning the thesis.

Italian and Community candidates wishing to submit qualifications referring to conditions and facts attested by Public Administrations must proceed exclusively with self-certification. Non-EU citizens legally residing in Italy may self-certify only data that can be verified or certified by Italian public bodies. They may also use declarations in lieu when provided for by an international convention between Italy and the declarant's country of origin.

Non-EU citizens not residing in Italy cannot self-certify.

Only the qualifications possessed by the candidate on the date the application form is submitted and submitted in accordance with the procedures set out in Article 5 will be assessed.

Failure to submit mandatory documents provided for in this article will constitute grounds for exclusion from the selection.

Art. 5

The submission of the applications for the present call starts on October 26, 2023 at 2:00 pm (Italian time) and ends on November 16, 2023 at 2:00 pm (Italian time).

The application to take part in the selection must be completed, under penalty of exclusion, using the appropriate online procedure, available at the link https://pica.cineca.it/

The procedure involves an applicant registration step, for those who do not already have an account, and then an application completion step.

Once completed, the online application must be signed in the manner described in the online procedure (manual signature with attached identity document or digital signature), under penalty of exclusion from selection. The application does not have to be signed if you access the above-mentioned online procedure using your SPID ID.

The qualifications referred to in Article 4 must be attached to the application in .pdf format. Individual .pdf files may not exceed 30MB.

The application for participation in the selection is automatically sent to the University of Udine with the definitive closing of the online procedure.

The University Administration:
- is not responsible if it is impossible to read the submitted documentation in electronic format due to damaged files;
- shall not accept or take into consideration qualifications or documents received in paper form or by any means other than what is specified in this article.

Reference to documents or publications already submitted in connection with other competitions is not allowed.

The Administration is not responsible for any missing document or communication because of inaccurate indication of residence and/or address submitted by the candidate during the application. Also, the Administration is not responsible if the candidate has not communicated changes in this information, or has communicated them too late. The Administration is also not responsible for any postal or telegraphic problems not attributable to the Administration itself.
Applicants are advised not to wait until the last few days before the closing date to submit their application. The University accepts no responsibility for any malfunctions due to technical problems and/or overloading of the communication line and/or application systems.

Art. 6
The selection procedure is held in accordance with the modality indicated in Attachment A.

The test will aim to assess the general preparation, experience and aptitude for research of the candidate. It will consist in the evaluation of the professional scientific curriculum, of the publications and qualifications presented, and of the interview, where foreseen.

Art. 7
The Examining board for the competition is identified in Attachment A of the present competition announcement, of which it is an integral part.

At its first meeting, the Examining board shall appoint its President and Secretary, and establish the criteria and methods for evaluating the qualifications and the interview, where foreseen.

The results of the qualifications assessment must be disclosed to applicants during the interview, where foreseen.

The Examining board can award a maximum of 100 points (one hundred out of one hundred) to the selection.

At the end of the evaluation procedure, the Examining board shall formulate the general merit list based on the overall score of each candidate, and draw up the minutes of the whole competition procedure.

Based on the ranking list, the assignment is awarded to candidates who have obtained a minimum overall score of 70/100 (seventy out of one hundred).

The Examining board's judgement is final.

The ranking list will be made public exclusively through publication on the University's official website.

Applicants will not be notified of the outcome of the evaluation.

Those who do not declare their acceptance of the research grant and do not present themselves at the research centre within the deadline communicated by the latter, even if not formally, shall lose the right to receive it. Exceptions to this term will only be granted in cases of documented force majeure.

The selected candidate will have to undergo any health assessment deemed necessary by the competent doctor and aimed at issuing the assessment of suitability for the specific task according to the protocol of the host structure. The signature of the contract will be possible only after obtaining the judgment of suitability for the specific task by the Azienda Sanitaria Universitaria Friuli Centrale (ASU FC). Before signature of the research grant contract, the candidate awarded of reference research grant must submit a copy of the vaccination booklet or related certificate, and intradermal reaction – sec. Mantoux (performed in the last 12 months).
Art. 8
The research activity cannot be started before signing the contract defining the terms and conditions of the collaboration.

The activity covered by the research grant must have the following characteristics:
a) it must be carried out as part of the research programme covered by the grant and not be a merely technical support to it;
b) it must have a close connection with the realization of the research program for which the winner of the grant has been awarded the contract;
c) it must be continuous and, in any case, temporally defined, not merely occasional, and in coordination with the overall activity of the University;
d) it must be carried out autonomously, solely within the limits of the programme prepared by the programme supervisor, without predetermined working hours.

The researcher is required to submit a detailed written report on the work carried out and the results achieved, accompanied by the opinion of the scientific supervisor, to the reference organisation at the intervals set out in the contract. The researcher must also submit interim reports and timesheets, if requested by the reference organisation.

Either the fellow or the reference organisation may withdraw from the contract.

The reference organisation may terminate the contract not only in the cases referred to in Article 9, sections 2 and 3, of the "Internal rules for awarding research grants pursuant to law 240 of 30 December 2010" of the University of Udine, but also in the event the research project and therefore the financial coverage on which the research grant is based cease to exist.

With regard to accident insurance and third-party liability, the provisions of art. 3 c. 5 of the "Internal rules for awarding research grants pursuant to Italian Law no. 240 of 30 December 2010" of the University of Udine, issued by Rector's Decree no. 182 of 31 March 2021, are applied. The Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), by authorizing with a subsequent deed the access of the selected candidate to its facilities, ensures insurance cover for professional risks and third-party liability in the course of the authorized activity. The insurance policy for accidents and occupational diseases remains at the expense of the selected candidate. In the absence of such policy, the selected candidate will not be allowed to access the facilities of the Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), and it will not be possible to proceed with the signature of the contract.

Art. 9
The following legal dispositions shall apply to the grant referred to in this call for applications:
- for tax matters, the provisions of Article 4 of Italian Law no. 476 of 13 August 1984, as subsequently amended and supplemented;
- for social security matters, the provisions of Article 2(26) et seq. of Italian Law no. 335 of 8 August 1995, as subsequently amended and supplemented;
- for mandatory maternity leave, the provisions of the Italian Ministerial Decree of 12 July 2007;
- with regard to sick leave, the provisions of Article 1(788) of Italian Law no. 296 of 27 December 2006 and subsequent amendments.

During the period of mandatory maternity leave, the allowance paid by INPS according to Art. 5 of the Italian Ministerial Decree of 12 July 2007 is supplemented by the University up to the full amount of the research grant.
The grant will be paid in monthly instalments.

Art. 10
The data collected as part of the procedure referred to in Art. 5 are necessary to properly manage the selection procedure, for any subsequent management of the research grant and for purposes related to managing services provided by the University. The University of Udine is the Data Controller. At any time, the data subject may request access, rectification and, depending on the University’s institutional purposes, cancellation and restriction of processing or oppose the processing of their data. The data subject can always lodge a complaint with the Italian Data Protection Authority. The complete disclosure is available on the University of Udine website in the “Privacy” section, accessible from the home page www.uniud.it Direct Link: https://www.uniud.it/it/it/pagine-speciali/guida/privacy

Art. 11
For all matters not expressly mentioned in this call for applications, refer to the regulations in force on the subject cited in the introduction and to the “Internal rules for awarding research grants pursuant to Italian Law no. 240 of 30 December 2010” of the University of Udine, issued by Rector’s Decree no. 182 of 31 March 2021.

Art. 12
The procedure supervisor is Dr Sandra Salvador, Head of the Research Services Area of the University of Udine.

The Responsible office at the University of Udine is “Area Servizi per la Ricerca - Ufficio Formazione per la Ricerca”, via Mantica n. 31 - 33100 Udine, Italia.

To request information about the call for applications, please complete the following form available on the University of Udine website:
https://helpdesk.uniud.it/SubmitSR.jsp?type=req&accountId=universityofudine&populateSR_id=42105
Nome e cognome / Name and surname: Tiziana Bove
Qualifica / Position: Professoressa Associata / Associate Professor
Dipartimento / Department: Area Medica / Medicine
Area MUR / Research field: 06 - Scienze Mediche / Medical Sciences
Settore concorsuale e Settore scientifico disciplinare / Scientific sector: 06/L1; MED/41 - Anestesiologia

Titolo dell’assegno di ricerca / Topic of the research fellowship “assegno di ricerca”:
I bandi sono consultabili dal sito dell’Ateneo, del MUR e di Euraxess / The calls are available on the University, MUR and Euraxess websites

Testo in italiano:
L’effetto aggiuntivo della Ketamina in combinazione con la terapia elettroconvulsiva nei disordini maggiori della depressione: uno studio traslazionale.

Text in English:
The additive effect of ketamine in combination with electroconvulsive stimulation (ECS) in major depressive disorder (MDD): a translational study.

Obiettivi previsti e risultati attesi del programma di ricerca in cui si colloca l’attività dell’assegnista di ricerca / Foreseen objectives and results of the research programme performed by the research fellow “assegnista di ricerca”:
I bandi sono consultabili dal sito dell’Ateneo, del MUR e di Euraxess / The calls are available on the University, MUR and Euraxess websites

Testo in italiano:
Il disturbo depressivo maggiore (MDD) è una malattia debilitante caratterizzata da almeno un episodio depressivo della durata di almeno 2 settimane e che comporta cambiamenti dell’umore e delle funzioni cognitive. I neurocircuiti cerebrali della MDD coinvolgono diverse regioni tra cui l’ippocampo e la corteccia prefrontale mediale (mPFC). Gli attuali trattamenti farmacologici per la depressione hanno un esordio terapeutico ritardato, che varia da diverse settimane a mesi, e vi è un’alta percentuale di individui che non rispondono mai al trattamento. Il National Institute for Health raccomanda la stimolazione elettroconvulsivante (ECS), nota negli esseri umani come terapia elettroconvulsivante, come opzione per i pazienti con disturbo depressivo maggiore se non hanno risposto a molteplici trattamenti farmacologici e psicologici. Tuttavia, i critici sostengono che la stimolazione elettroconvulsivante provoca invariabilmente disturbi cognitivi. La ketamina è un anestetico utilizzato nell'anestesia ECS. È interessante notare che la ketamina a dosi sub-anestetiche è un antidepressivo ad azione rapida con efficacia per i sintomi della depressione resistenti al trattamento. Nonostante questi risultati, manca la prova del concetto che la ketamina a dosi sub-anestetiche può potenziare gli effetti antidepressivi dell’ECS alleviando allo stesso tempo gli effetti avversi cognitivi correlati all’ECS, accelerando così il miglioramento sintomatico.

Utilizzando un approccio multidisciplinare che spazia da paradigmi comportamentali, elettrofisiologia, optogenetica, morfologia e analisi biochimica, indagheremo innanzitutto la capacità della ketamina di potenziare l’effetto antidepressivo della stimolazione elettroconvulsiva senza causare deterioramento cognitivo correlato alla stimolazione elettroconvulsiva in un modello murino di depressione. Inoltre, studieremo come la combinazione di ketamina ed ECS avrà un impatto sui circuiti neuronali e sui biomarcatori nelle regioni cerebrali coinvolte nel disturbo depressivo maggiore.
A tal fine, proponiamo di eseguire sia uno studio preclinico che uno studio clinico per valutare l'effetto additivo della ketamina con la stimolazione elettroconvulsivante nella depressione.

I dati preclinici forniranno:
1) dati comportamentali, morfologici e neurochimici che svelano il meccanismo della combinazione di ketamina e stimolazione elettroconvulsivante nei topi sottoposti a stress cronico;
2) il nesso causale tra alterazioni elettrofisiologiche ed esiti comportamentali in topi stressati in seguito alla somministrazione di ketamina in combinazione con stimolazione elettroconvulsivante.

Nei pazienti con disturbo depressivo maggiore ci si aspetta di identificare:
1) un pannello di dati clinici associati alla risposta alla ketamina e alla stimolazione elettroconvulsivante;
2) andamenti specifici dei marcatori ematici associati al trattamento farmacologico e alla stimolazione elettroconvulsivante.

Successivamente, studieremo la capacità della ketamina come componente aggiuntivo nella stimolazione elettroconvulsivante di modulare il comportamento e i livelli di biomarcatori plasmatici nei pazienti con disturbo depressivo maggiore. Per correlare i dati sugli animali con quelli umani e massimizzare l'impatto traslazionale di questo studio, condurremo uno studio randomizzato e controllato in doppio cieco per testare:
1) la capacità della ketamina di potenziare gli effetti antidepressivi della stimolazione elettrica senza produrre disturbi cognitivi nei pazienti con disturbo depressivo maggiore;
2) come questo regime modulerà i livelli plasmatici di glutammato, d-aspartato, Trp, 5-HT e 5-HIAA, nonché quelli di glutammato e aspartato.

L’attività dell’assegnista di ricerca, finalizzata alla realizzazione del progetto dal titolo “The additive effect of ketamine in combination with electroconvulsive stimulation (ECS) in major depressive disorder (MDD): a translational study” sarà prevalentemente incentrata su:
- identificazione dei centri italiani che attualmente utilizzano la stimolazione elettroconvulsivante come trattamento del disturbo depressivo maggiore;
- gestione del processo amministrativo/etico di approvazione e attivazione sperimentazioni cliniche;
- gestione dei dati clinici e della documentazione richiesta in relazione alle sperimentazioni cliniche;
- data entry, attività di monitoraggio, data analysis;
- gestione dei rapporti con gli altri centri coinvolti nella sperimentazione.

L'assegnista di ricerca dovrà altresì rispettare tutte le norme organizzative interne delle strutture ospedaliere ed universitarie di riferimento nello svolgimento della ricerca. L'assegnista di ricerca è tenuto a mantenere la massima riservatezza relativamente a tutte le informazioni ed ai dati clinici, tecnici, scientifici e didattici appresi durante lo svolgimento delle attività inerenti all’assegno di ricerca, ai sensi della normativa in tema di privacy vigente.

Text in English:
Major depressive disorder (MDD) is a debilitating disease that is characterized by at least one depressive episode lasting at least 2 weeks and involving changes in mood and in cognition. The brain neurocircuitries of MDD involve several regions including the hippocampus and the medial prefrontal cortex (mPFC). Current pharmacological treatments for depression have a delayed therapeutic onset, ranging from several weeks to months, and there is a high percentage of individuals who never respond to treatment. National Institute for Health recommends electroconvulsive stimulation (ECS), known in humans as electroconvulsive therapy, as an option for patients with major depressive disorder if they have not responded to multiple drug and psychological treatments. However, critics contend that electroconvulsive stimulation invariably results in cognitive impairments. Ketamine is an anaesthetic that has been used in ECS anaesthesia. Interestingly, ketamine at sub-anaesthetic dose is a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of depression. Despite these findings, the proof of concept that ketamine at sub-anaesthetic dose can potentiate ECS’
antidepressant effects alleviating at the same time ECS-related cognitive adverse effects, thus accelerating symptomatic improvement, is lacking.

Employing a multidisciplinary approach spanning from behavioral paradigms, electrophysiology, optogenetics, morphology and biochemical analysis, we will first investigate the ability of ketamine to potentiate the antidepressant effect of the electroconvulsive stimulation without causing cognitive impairment related to electroconvulsive stimulation in a mouse model of depression. Moreover, we will study how the combination of ketamine and ECS will impact neuronal circuitries and biomarkers in brain regions involved in major depressive disorder.

To this end, we here propose to perform both a preclinical and a clinical study to assess the additive effect of ketamine with electroconvulsive stimulation in depression. Preclinical data will provide:

1) Behavioural, morphological and neurochemical data unveiling the mechanism of the combination of ketamine and electroconvulsive stimulation in mice under chronic stress;
2) The causal link between electrophysiological alterations and behavioural outcomes in stressed mice following the administration of ketamine in combination with electroconvulsive stimulation.

In major depressive disorder patients, we expect to identify:

1) A panel of clinical data associated with response to ketamine and electroconvulsive stimulation
2) Specific trends of blood markers associated with the pharmacological treatment and electroconvulsive stimulation.

Next, we will study the ability of ketamine as add-on in electroconvulsive stimulation to modulate the behavior as well as plasmatic biomarkers levels in major depressive disorder patients. To correlate animal with human data and maximize the translational impact of this study, we will conduct a randomized double-blind controlled trial to test:

1) The ability of ketamine to potentiate the antidepressant effects of electrical stimulation without producing cognitive impairments in major depressive disorder patients;
2) How this regimen will modulate the plasmatic levels of glutamate, d-aspartate, Trp, 5-HT, and 5-HIAA, as well as those of glutamate and aspartate.

The activity of the research fellow, aimed at the realization of the project entitled “The additive effect of ketamine in combination with electroconvulsive stimulation (ECS) in major depressive disorder (MDD): a translational study”, will mainly focus on:

- Identification of Italian centers that currently use electroconvulsive stimulation as a treatment for major depressive disorder;
- Management of the administrative/ethical process of approval and activation of clinical trials;
- Management of clinical data and documentation required in relation to clinical trials;
- Data entry, monitoring activities, data analysis;
- Management of relationships with the other centers involved in the trial.

The research fellow must also comply with all the internal organizational rules of the relevant hospital and university structures when carrying out the research. The research fellow is required to maintain maximum confidentiality regarding all clinical, technical, scientific and educational information and data learned during the performance of activities relating to the research grant, in accordance with current privacy legislation.

**Struttura dell’Università di Udine presso la quale verrà sviluppata l’attività di ricerca / Department or other structure of the University of Udine where research activities will be carried out:**

Dipartimento di Area Medica / Department of Medicine
Tipologia di attività assistenziale prevista in relazione alle esigenze del programma di ricerca / 
Type of care activity scheduled in relation to the needs of the research program:

Nessun contatto con pazienti ma solo con dati clinici sensibili. / No contact with patients but only with sensitive clinical data.

Struttura ospedaliera coinvolta / Hospital facility involved:

Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) SOC Clinica di Anestesia e Rianimazione.

Importo dell’assegno di ricerca (al lordo oneri carico assegnista) / Total grant gross for the research fellowship:

€ 20.266,72

Durata dell’assegno di ricerca / Duration of the research fellowship “assegno di ricerca”:

12 mesi / months

Finanziamento / Financed by:


Requisiti di ammissione / Minimum qualifications necessary:

- Possesso di un diploma di laurea vecchio ordinamento (ante decreto 3 novembre 1999 n. 509) o di laurea specialistica/magistrale (ex decreto 3 novembre 1999 n. 509 e decreto 22 ottobre 2004 n. 270) o titolo equivalente conseguito all’estero;
- Diploma di specializzazione in area medica con adeguata produzione scientifica;
- Iscrizione all’Albo dei Medici chirurghi dell’Ordine dei Medici Chirurghi e degli Odontoiatri;
- possesso di un curriculum scientifico professionale idoneo allo svolgimento dell’attività di ricerca contemplata.
- University degree obtained before Decree n. 509 of 3 November 1999 or specialistic/Master’s degree (post decree n. 509 of 3 November 1999 and decree n. 270 of 22 October 2004) or equivalent degree obtained abroad;
- Medical specialization accompanied by an adequate scientific production or equivalent title obtained abroad;
- Enrollment in the registrar of Medical Surgeons of the Order of Medical Surgeons and Dentists in the province where the candidate is living;
- professional scientific curriculum suitable for the research activity above mentioned.

Procedura selettiva / Competition procedure:

Valutazione per soli titoli / Assessment of qualifications only
**Commissione giudicatrice / Examining Board:**

<table>
<thead>
<tr>
<th>Nome e Cognome</th>
<th>Qualifica</th>
<th>SSD</th>
<th>Università</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Membri Effettivi / Permanent members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiziana Bove</td>
<td>PA</td>
<td>MED/41</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td>Umberto Baccarani</td>
<td>PA</td>
<td>MED/18</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td>Sergio Giuseppe Intini</td>
<td>RU</td>
<td>MED/18</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td><strong>Membri Supplenti / Temporary members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giovanni Terrosu</td>
<td>PA</td>
<td>MED/18</td>
<td>Università degli Studi di Udine</td>
</tr>
<tr>
<td>Luca Quartuccio</td>
<td>PA</td>
<td>MED/16</td>
<td>Università degli Studi di Udine</td>
</tr>
</tbody>
</table>